Literature DB >> 9321821

Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response.

J J Lopez1, R J Laham, J P Carrozza, M Tofukuji, F W Sellke, S Bunting, M Simons.   

Abstract

Vascular endothelial growth factor (VEGF) has been utilized to improve blood flow in the setting of myocardial or peripheral vascular ischemia. In this investigation we studied the hemodynamic effects of intracoronary VEGF administration. Hemodynamic parameters and Doppler flow wire recordings from the left anterior descending coronary artery were measured after intracoronary infusion of VEGF (1, 10, and 100 micrograms) in 28 intubated pigs. Additional studies were performed using an in vitro isolated microvessel preparation. VEGF produced a highly significant dose-dependent increase in coronary blood flow (maximal 3.51 +/- 0.85-fold) in the absence of significant changes in epicardial artery diameter, a decline in mean arterial pressure (maximal 43%), and a decrease in left ventricular end-diastolic pressure (maximal 52%), all of which could be inhibited by pretreatment with NG-nitro-L-arginine. The increase in coronary flow seen with 10 or 100 micrograms VEGF was significantly greater than the maximal vasodilation achieved with serotonin or nitroglycerin and was equivalent to a maximal adenosine response. In summary, VEGF stimulates nitric oxide (NO)-dependent dilation of coronary microvessels, and repeat administrations of VEGF resulted in rapid development of tachyphylaxis to VEGF as well as serotonin, but not to nitroglycerin or adenosine, which appeared to be secondary to impaired NO production.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9321821     DOI: 10.1152/ajpheart.1997.273.3.H1317

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  15 in total

1.  Vascular endothelial growth factor and the in vivo increase in plasma extravasation in the hamster cheek pouch.

Authors:  M Félétou; J Staczek; J Duhault
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Therapeutic Angiogenesis for Coronary Artery Disease.

Authors:  Tanveer A. Khan; Frank W. Sellke; Roger J. Laham
Journal:  Curr Treat Options Cardiovasc Med       Date:  2002-02

3.  Postinfarct intramyocardial injection of mesenchymal stem cells pretreated with TGF-alpha improves acute myocardial function.

Authors:  Jeremy L Herrmann; Aaron M Abarbanell; Brent R Weil; Yue Wang; Jeffrey A Poynter; Mariuxi C Manukyan; Daniel R Meldrum
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-05-19       Impact factor: 3.619

Review 4.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

5.  Downstream exposure to growth factors causes elevated velocity and dilation in arteriolar networks.

Authors:  Melissa K Georgi; Anthony M Dewar; Mary D Frame
Journal:  J Vasc Res       Date:  2010-07-06       Impact factor: 1.934

Review 6.  Cell communications in the heart.

Authors:  Daniela Tirziu; Frank J Giordano; Michael Simons
Journal:  Circulation       Date:  2010-08-31       Impact factor: 29.690

7.  Control growth factor release using a self-assembled [polycation:heparin] complex.

Authors:  Blaine J Zern; Hunghao Chu; Yadong Wang
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

8.  Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis.

Authors:  Tilman Ziegler; Jan Horstkotte; Claudia Schwab; Vanessa Pfetsch; Karolina Weinmann; Steffen Dietzel; Ina Rohwedder; Rabea Hinkel; Lisa Gross; Seungmin Lee; Junhao Hu; Oliver Soehnlein; Wolfgang M Franz; Markus Sperandio; Ulrich Pohl; Markus Thomas; Christian Weber; Hellmut G Augustin; Reinhard Fässler; Urban Deutsch; Christian Kupatt
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

Review 9.  Endothelium-driven myocardial growth or nitric oxide at the crossroads.

Authors:  Daniela Tirziu; Michael Simons
Journal:  Trends Cardiovasc Med       Date:  2008-11       Impact factor: 6.677

Review 10.  Protein-, gene-, and cell-based therapeutic angiogenesis for the treatment of myocardial ischemia.

Authors:  Marc Ruel; Jianming Song; Frank W Sellke
Journal:  Mol Cell Biochem       Date:  2004-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.